Polymeric Nanocarriers of Drug Delivery Systems in Cancer Therapy
Open Access
- 24 March 2020
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (4), 298
- https://doi.org/10.3390/pharmaceutics12040298
Abstract
Conventional chemotherapy is the most common therapeutic method for treating cancer by the application of small toxic molecules thatinteract with DNA and causecell death. Unfortunately, these chemotherapeutic agents are non-selective and can damage both cancer and healthy tissues, producing diverse side effects, andthey can have a short circulation half-life and limited targeting. Many synthetic polymers have found application as nanocarriers of intelligent drug delivery systems (DDSs). Their unique physicochemical properties allow them to carry drugs with high efficiency, specificallytarget cancer tissue and control drug release. In recent years, considerable efforts have been made to design smart nanoplatforms, including amphiphilic block copolymers, polymer-drug conjugates and in particular pH- and redox-stimuli-responsive nanoparticles (NPs). This review is focused on a new generation of polymer-based DDSs with specific chemical functionalities that improve their hydrophilicity, drug loading and cellular interactions.Recentlydesigned multifunctional DDSs used in cancer therapy are highlighted in this review.Keywords
This publication has 99 references indexed in Scilit:
- Codelivery of curcumin and doxorubicin by MPEG-PCL results in improved efficacy of systemically administered chemotherapy in mice with lung cancerInternational Journal of Nanomedicine, 2013
- P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cellsNanomedicine, 2012
- Aptamer-functionalized PEG–PLGA nanoparticles for enhanced anti-glioma drug deliveryBiomaterials, 2011
- A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumoursBritish Journal of Cancer, 2011
- HPMA copolymers: Origins, early developments, present, and future☆Advanced Drug Delivery Reviews, 2009
- Antibody-modified liposomes for cancer chemotherapyExpert Opinion on Drug Delivery, 2008
- A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulationBritish Journal of Cancer, 2007
- Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivoProceedings of the National Academy of Sciences of the United States of America, 2006
- Multifunctional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug deliveryMolecular BioSystems, 2005
- AP-5346Drugs of the Future, 2004